TOKYO -- The shroud of secrecy was thick, but the Takeda Pharmaceutical director saw and heard enough to make him shudder.
The director was attending a board meeting at the drugmaker's Tokyo headquarters in February. On the table was a document detailing another, anonymous drug company. Takeda President and CEO Christophe Weber said he was looking at acquiring a peer roughly the same size as Takeda.
